SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for LSB INDUSTRIES, (LXU) — Nov 19, 2021

LSB INDUSTRIES, INC.
Date: Nov. 19, 2021 · CIK: 0000060714 · Accession: 0000000000-21-014075

AI Filing Summary & Sentiment

File numbers found in text: 333-261131

Date
November 19, 2021
Author
Not clearly detected
Form
UPLOAD
Company
LSB INDUSTRIES, INC.

Letter

United States securities and exchange commission logo November 19, 2021 Mark T. Behrman President and Chief Executive Officer LSB INDUSTRIES INC 3503 NW 63RD Street, Suite 500 Oklahoma City, Oklahoma 73116 Re:LSB INDUSTRIES INC Registration Statement on Form S-3 Filed November 16, 2021 File No. 333-261131 Dear Mr. Behrman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Craig E. Marcus, Esq.

Show Raw Text
United States securities and exchange commission logo
November 19, 2021
Mark T. Behrman
President and Chief Executive Officer
LSB INDUSTRIES INC
3503 NW 63RD Street, Suite 500
Oklahoma City, Oklahoma 73116
Re:LSB INDUSTRIES INC
Registration Statement on Form S-3
Filed November 16, 2021
File No. 333-261131
Dear Mr. Behrman:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Craig E. Marcus, Esq.